Alkem Laboratories (ALKEM.NS) Stock Price

Alkem Laboratories Price

NSE·CLOSED
5,598.50INR-21.50 (-0.38 %)
Market closed

Over the last 14 years Alkem Laboratories grew revenue by 15.7% annually, reaching 129.65 B INR. Earnings per share have grown at 15.3% per year over the last 14 years. For Alkem Laboratories, the net margin of 16.7% is down versus 17.9% a few years ago. At today's price the dividend yield works out to roughly 0.80%. The payout ratio is around 25% of earnings. The dividend has grown at 12.4% per year over the past 9 years. The consensus 12-month price target for Alkem Laboratories is 6,007.80 INR, about 7.3% above where the stock trades today. Of 27 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.

Alkem Laboratories stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Alkem Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Alkem Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Alkem Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Alkem Laboratories Stock Price History
DateAlkem Laboratories Price
8/10/20265,598.50 INR
8/7/20265,620.00 INR
8/6/20265,597.50 INR
8/5/20265,696.50 INR
8/4/20265,694.50 INR
7/31/20265,751.50 INR
7/30/20265,759.00 INR
7/28/20265,616.50 INR
7/27/20265,613.00 INR
7/24/20265,633.50 INR
7/23/20265,598.00 INR
7/22/20265,585.00 INR
7/21/20265,681.50 INR
7/20/20265,653.50 INR
7/17/20265,631.00 INR
7/15/20265,659.00 INR
7/14/20265,601.50 INR
7/13/20265,567.00 INR
7/10/20265,669.50 INR
7/9/20265,648.50 INR
7/8/20265,606.00 INR
7/7/20265,667.50 INR
7/6/20265,598.50 INR
7/3/20265,575.00 INR
7/2/20265,500.50 INR
7/1/20265,567.50 INR
6/30/20265,570.00 INR
6/29/20265,416.50 INR
6/25/20265,425.00 INR
6/24/20265,428.50 INR
6/23/20265,415.50 INR
6/22/20265,367.00 INR
6/19/20265,373.50 INR
6/18/20265,372.00 INR
6/17/20265,347.50 INR
6/16/20265,348.00 INR
6/15/20265,351.50 INR
6/12/20265,298.00 INR
6/11/20265,301.50 INR
6/10/20265,365.00 INR
6/9/20265,355.50 INR
6/8/20265,356.50 INR
6/5/20265,251.50 INR
6/4/20265,276.50 INR
6/3/20265,274.00 INR
6/2/20265,239.00 INR
6/1/20265,314.50 INR
5/29/20265,498.00 INR
5/27/20265,451.50 INR
5/26/20265,380.00 INR
5/25/20265,400.50 INR
5/22/20265,404.50 INR
5/21/20265,501.50 INR
5/20/20265,490.50 INR
5/19/20265,470.00 INR
5/18/20265,468.00 INR
5/15/20265,486.00 INR
5/14/20265,576.50 INR
5/13/20265,462.50 INR
5/12/20265,496.50 INR
5/11/20265,599.50 INR
5/8/20265,585.50 INR
5/7/20265,590.50 INR
5/6/20265,557.00 INR
5/5/20265,403.00 INR
5/4/20265,360.50 INR
5/1/20265,400.00 INR
4/30/20265,400.00 INR
4/29/20265,344.00 INR
4/28/20265,418.50 INR
4/27/20265,344.00 INR
4/24/20265,235.00 INR
4/23/20265,520.50 INR
4/22/20265,627.00 INR
4/21/20265,696.50 INR
4/20/20265,642.00 INR
4/17/20265,582.00 INR
4/16/20265,570.00 INR
4/15/20265,575.50 INR
4/13/20265,364.50 INR
4/10/20265,440.00 INR
4/9/20265,370.50 INR
4/8/20265,246.00 INR
4/7/20265,172.50 INR
4/6/20265,236.50 INR
4/2/20265,258.00 INR
4/1/20265,250.50 INR
3/30/20265,300.00 INR
3/27/20265,344.50 INR
3/25/20265,434.50 INR
3/24/20265,301.00 INR
3/23/20265,160.00 INR
3/20/20265,280.00 INR
3/19/20265,257.00 INR
3/18/20265,360.50 INR
3/17/20265,350.00 INR
3/16/20265,290.00 INR
3/13/20265,384.00 INR
3/12/20265,451.00 INR
3/11/20265,530.00 INR
3/10/20265,601.00 INR
3/9/20265,471.00 INR
3/6/20265,525.00 INR
3/5/20265,541.50 INR
2/26/20265,760.00 INR
2/25/20265,646.00 INR
2/23/20265,487.00 INR
2/20/20265,395.00 INR
2/19/20265,372.50 INR
2/18/20265,460.50 INR
2/17/20265,460.00 INR
2/16/20265,475.00 INR
2/13/20265,400.00 INR
2/12/20265,857.00 INR
2/11/20265,885.00 INR
2/10/20265,781.00 INR
2/9/20265,736.00 INR
2/6/20265,587.50 INR
2/5/20265,649.00 INR
2/4/20265,660.00 INR
2/3/20265,695.00 INR
2/2/20265,530.00 INR
1/30/20265,655.50 INR
1/29/20265,713.00 INR
1/28/20265,720.00 INR
1/27/20265,754.00 INR
1/23/20265,749.00 INR
1/22/20265,758.50 INR
1/21/20265,630.00 INR
1/20/20265,673.00 INR
1/19/20265,725.00 INR
1/16/20265,840.00 INR
1/14/20265,822.50 INR
1/13/20265,863.50 INR
1/12/20265,886.00 INR
1/9/20265,785.50 INR
1/8/20265,790.00 INR
1/7/20265,792.00 INR
1/6/20265,655.50 INR
1/5/20265,552.50 INR
1/2/20265,585.00 INR
1/1/20265,465.00 INR
12/31/20255,470.00 INR
12/30/20255,432.00 INR
12/29/20255,481.00 INR
12/26/20255,537.00 INR
12/24/20255,552.00 INR
12/23/20255,600.00 INR
12/22/20255,619.50 INR
12/19/20255,582.50 INR
12/18/20255,506.00 INR
12/17/20255,627.50 INR
12/16/20255,663.50 INR
12/15/20255,611.00 INR
12/12/20255,614.50 INR
12/11/20255,618.50 INR
12/10/20255,582.00 INR
12/9/20255,672.00 INR
12/8/20255,595.00 INR
12/5/20255,685.00 INR
12/4/20255,638.50 INR
12/3/20255,648.00 INR
12/2/20255,625.00 INR
12/1/20255,590.00 INR
11/28/20255,677.50 INR
11/27/20255,680.00 INR
11/26/20255,777.00 INR
11/25/20255,699.00 INR
11/24/20255,606.00 INR
11/21/20255,709.00 INR
11/20/20255,692.00 INR
11/19/20255,743.00 INR
11/18/20255,713.00 INR
11/17/20255,725.00 INR
11/14/20255,720.00 INR
11/13/20255,703.00 INR
11/12/20255,770.00 INR
11/11/20255,700.00 INR
11/10/20255,660.00 INR
11/7/20255,670.00 INR
11/6/20255,631.50 INR
11/4/20255,633.00 INR
11/3/20255,628.50 INR
10/31/20255,505.50 INR
10/30/20255,510.00 INR
10/29/20255,544.00 INR
10/28/20255,440.00 INR
10/27/20255,449.00 INR
10/24/20255,545.00 INR
10/23/20255,525.00 INR
10/21/20255,523.00 INR
10/20/20255,545.00 INR
10/17/20255,587.00 INR
10/16/20255,542.00 INR
10/15/20255,566.50 INR
10/14/20255,500.00 INR
10/13/20255,509.00 INR
10/10/20255,454.50 INR
10/9/20255,472.00 INR
10/8/20255,499.00 INR
10/7/20255,491.00 INR
10/6/20255,491.50 INR
10/3/20255,428.00 INR
10/1/20255,469.00 INR
9/30/20255,425.00 INR
9/29/20255,409.00 INR
9/26/20255,433.00 INR
9/25/20255,508.00 INR
9/24/20255,576.00 INR
9/23/20255,570.50 INR
9/22/20255,486.00 INR
9/19/20255,554.00 INR
9/18/20255,480.50 INR
9/17/20255,459.50 INR
9/16/20255,509.00 INR
9/15/20255,498.00 INR
9/12/20255,445.00 INR
9/11/20255,400.00 INR
9/10/20255,320.50 INR
9/9/20255,335.50 INR
9/8/20255,315.00 INR
9/5/20255,339.00 INR
9/4/20255,300.50 INR
9/3/20255,289.00 INR
9/2/20255,251.00 INR
9/1/20255,327.50 INR
8/29/20255,303.50 INR
8/28/20255,361.00 INR
8/26/20255,422.00 INR
8/25/20255,411.00 INR
8/22/20255,426.00 INR
8/21/20255,443.00 INR
8/20/20255,393.00 INR
8/19/20255,400.00 INR
8/18/20255,360.00 INR
8/14/20255,347.50 INR
8/13/20255,379.50 INR
Access this data via the Eulerpool API
Get Free API Key

Alkem Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
106.34 B INR
17.73 B INR
16.46 B INR
Jan 1, 2023
115.99 B INR
13.84 B INR
9.84 B INR
Jan 1, 2024
126.68 B INR
19.87 B INR
17.96 B INR
Jan 1, 2025
129.65 B INR
21.82 B INR
21.65 B INR
Jan 1, 2026 (e)
146.21 B INR
25.80 B INR
25.16 B INR
Jan 1, 2027 (e)
165.68 B INR
29.23 B INR
23.78 B INR
Jan 1, 2028 (e)
183.97 B INR
32.46 B INR
27.37 B INR
Jan 1, 2029 (e)
202.39 B INR
35.71 B INR
31.83 B INR

Alkem Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 10:57 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
31.2637.4150.4858.5364.3173.5783.4488.65106.34115.99126.68129.65146.21165.68183.97202.39
25.2819.6834.9315.949.8914.4013.426.2419.969.089.212.3412.7813.3211.0410.01
54.5052.9057.1357.2959.2058.3859.0259.5159.9057.4960.3162.6362.6362.6362.6362.63
17.0419.7928.8433.5338.0742.9549.2552.7663.7066.6976.3981.2091.57103.77115.22126.76
3.884.337.949.018.929.6112.9016.7017.7313.8419.8721.8225.8029.2332.4635.71
12.4111.5715.7315.3913.8713.0615.4618.8316.6711.9315.6816.8317.6417.6417.6417.64
4.353.927.428.926.317.6111.2715.8516.469.8417.9621.6525.1623.7827.3731.83
13.42-10.0489.3820.28-29.2720.5448.2140.633.82-40.2082.4720.5916.19-5.4715.0916.29
––15.7012.0013.0016.0025.0030.0034.0035.0090.0084.0051.0061.2073.44–
–––-23.578.3323.0856.2520.0013.332.94157.14-6.67-39.2920.0020.00–
120.00120.00120.00120.00120.00120.00120.00120.00120.00119.57119.57119.57119.57119.57119.57119.57
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Alkem Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Alkem Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Alkem Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Alkem Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Alkem Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Alkem Laboratories stock margins

The Alkem Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alkem Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alkem Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
59.51 %
18.83 %
17.88 %
Jan 1, 2022
59.90 %
16.67 %
15.47 %
Jan 1, 2023
57.49 %
11.93 %
8.48 %
Jan 1, 2024
60.31 %
15.68 %
14.18 %
Jan 1, 2025
62.63 %
16.83 %
16.70 %
Jan 1, 2026 (e)
62.63 %
17.64 %
17.21 %
Jan 1, 2027 (e)
62.63 %
17.64 %
14.35 %
Jan 1, 2028 (e)
62.63 %
17.64 %
14.88 %

Alkem Laboratories Stock Revenue, EBIT, Earnings per Share

The Alkem Laboratories earnings per share therefore indicates how much revenue Alkem Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
738.75 INR
139.13 INR
132.08 INR
Jan 1, 2022
886.18 INR
147.72 INR
137.13 INR
Jan 1, 2023
970.12 INR
115.78 INR
82.31 INR
Jan 1, 2024
1,059.47 INR
166.15 INR
150.19 INR
Jan 1, 2025
1,084.31 INR
182.46 INR
181.11 INR
Jan 1, 2026 (e)
1,222.91 INR
215.75 INR
210.43 INR
Jan 1, 2027 (e)
1,385.74 INR
244.47 INR
198.92 INR
Jan 1, 2028 (e)
1,538.75 INR
271.47 INR
228.93 INR

Alkem Laboratories business model & stock analysis

Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally.

Alkem Laboratories SWOT Analysis

Strengths

Alkem Laboratories Ltd has several strengths that contribute to its success in the pharmaceutical industry. These include:

  • Strong market presence: Alkem Laboratories Ltd is one of the leading pharmaceutical companies in India, with a significant market share.
  • Diverse product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic categories, providing a competitive edge.
  • Strong research and development (R&D) capabilities: Alkem Laboratories Ltd invests significantly in R&D to develop innovative and high-quality drugs, ensuring its ability to meet market demands.
  • Established manufacturing facilities: The company has state-of-the-art manufacturing facilities that adhere to strict quality standards, ensuring the production of safe and effective medicines.
  • Experienced management team: Alkem Laboratories Ltd boasts a skilled and experienced management team that drives its strategic growth and decision-making processes.

Weaknesses

Despite its strengths, Alkem Laboratories Ltd faces certain weaknesses that could potentially hinder its performance:

  • Dependence on regulatory approvals: The company's operations are subject to regulatory approvals, which can sometimes lead to delays in product launches and affect its market position.
  • Reliance on a single geographic region: Alkem Laboratories Ltd predominantly operates in India, which exposes it to country-specific risks and limits its global footprint.
  • Intense competition: The pharmaceutical industry is highly competitive, and Alkem Laboratories Ltd faces fierce competition from both domestic and international players.

Opportunities

Alkem Laboratories Ltd can capitalize on the following opportunities to further enhance its business growth:

  • Expanding global presence: The company could explore opportunities for expansion into international markets, diversifying its revenue streams and reducing dependence on a single region.
  • Increasing demand for generics: With the rising focus on affordable healthcare, there is an increasing demand for generic drugs, offering Alkem Laboratories Ltd the chance to expand its generic product offering.
  • Investing in advanced technologies: Embracing technological advancements such as artificial intelligence and data analytics can enable the company to improve operational efficiency, research capabilities, and customer experience.

Threats

Alkem Laboratories Ltd must also be cautious of potential threats that could impact its business:

  • Regulatory challenges: Changes in regulations and government policies can pose challenges to the company's operations and impact its market position.
  • Pricing pressures: The pharmaceutical industry faces pricing pressures, with governments and healthcare providers demanding lower prices, which may affect Alkem Laboratories Ltd's profitability.
  • Intellectual property rights infringement: The company may face risks related to the infringement of its intellectual property rights, leading to revenue loss and erosion of its competitive advantage.
  • Global economic uncertainties: Worldwide economic fluctuations and uncertainties could impact Alkem Laboratories Ltd's business performance, including currency exchange rates and market demand.

Alkem Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Alkem Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Alkem Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Alkem Laboratories shares outstanding

The number of shares of Alkem Laboratories was 119.57 M in 2025. This indicates how many shares Alkem Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
120.00 M Stocks
Jan 1, 2022
120.00 M Stocks
Jan 1, 2023
119.57 M Stocks
Jan 1, 2024
119.57 M Stocks
Jan 1, 2025
119.57 M Stocks
Jan 1, 2026 (e)
119.57 M Stocks
Jan 1, 2027 (e)
119.57 M Stocks
Jan 1, 2028 (e)
119.57 M Stocks

Alkem Laboratories Dividend History

11 years of dividend payments · 8 consecutive increases

YearAnnual DividendYoY ChangePayments
202643.00INRYTD—1×
Feb 20, 202643.00INR↑ 437.5%1/1
202545.00INR↑ 12.5%2×
Feb 14, 202537.00INR↑ 640.0%1/2
Aug 8, 20258.00INR↓ 78.4%2/2
202440.00INR↑ 14.3%2×
202335.00INR↑ 2.9%2×
202234.00INR↑ 13.3%2×
202130.00INR↑ 20.0%2×
202025.00INR↑ 56.3%2×
201916.00INR↑ 23.1%2×
201813.00INR↑ 44.4%2×
20179.00INR↓ 42.7%1×

Alkem Laboratories dividend history and estimates

In 2025, Alkem Laboratories paid a dividend amounting to 45.00 INR. Dividend means that Alkem Laboratories distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
30.00 INR
0.00 INR
0.00 INR
Jan 1, 2022
34.00 INR
0.00 INR
0.00 INR
Jan 1, 2023
35.00 INR
0.00 INR
0.00 INR
Jan 1, 2024 (e)
40.00 INR
50.00 INR
0.00 INR
Jan 1, 2025 (e)
45.00 INR
39.00 INR
0.00 INR
Jan 1, 2026
51.00 INR
0.00 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
61.20 INR
0.00 INR
Jan 1, 2028 (e)
0.00 INR
73.44 INR
25.00 INR

Alkem Laboratories dividend payout ratio

In 2025, Alkem Laboratories had a payout ratio of 24.85%. The payout ratio indicates the percentage of the company's profits that Alkem Laboratories distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
22.71 %
Jan 1, 2022
24.79 %
Jan 1, 2023
42.52 %
Jan 1, 2024
26.63 %
Jan 1, 2025
24.85 %
Jan 1, 2026 (e)
24.24 %
Jan 1, 2027 (e)
30.77 %
Jan 1, 2028 (e)
32.08 %

Current Alkem Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.84 %
Buy
55.56 % (15)
Hold
29.63 % (8)
Sell
14.81 % (4)
12M Price Target
6,007.80
Last Price
5,598.50
Currency
INR
12M Return Potential
7.31 %
LTM Return
0 %

Alkem Laboratories Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/17/202430.80INR-32.61 BINR-2024 Q4
2/8/202439.24INR-33.46 BINR-2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Alkem Laboratories stock

48/100
69
Environment
50
Social
24
Governance
E

Environment

20
Scope 1 - Direct Emissions19,249
Scope 2 - Indirect emissions from purchased energy82,319
Scope 3 - Indirect emissions within the value chain365,176
Total CO₂ emissions101,568
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees2.559
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Alkem Laboratories shareholder structure

% Name
18.81389%
Singh (Sarandhar)
Singh (Sarandhar)
8.77117%
Singh (Madhurima)
Singh (Madhurima)
7.27280%
Singh (Basudeo Narain)
Singh (Basudeo Narain)
6.42523%
Singh (Mritunjay Kumar)
Singh (Mritunjay Kumar)
3.85779%
HDFC Life Insurance Company Limited
HDFC Life Insurance Company Limited
3.52533%
ICICI Prudential Asset Management Co. Ltd.
ICICI Prudential Asset Management Co. Ltd.
...

Alkem Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
33.9%
Float Shares
-
Shares Outstanding
-

Alkem Laboratories Executives and Management Board

16 members · avg. age 64 · 19 % women

VG

Dr. Vikas Gupta

Chief Executive Officer

108.60 M INR

Management

SS

Mr. Sandeep Singh (42)

Managing Director, Executive Director · since 2017

97.50 M INR
MN

Mr. Manish Narang

President - Legal, Chief Compliance Officer, Company Secretary · since 2020

18.35 M INR
NA

Mr. Nitin Agrawal

President - Finance, Chief Financial Officer

14.35 M INR
PS

Ms. Purvi Shah

Investor Relations · since 2024

–

Board of Directors

BS

Mr. Basudeo Singh (83)

Executive Chairman of the Board · since 2021

214.30 M INR
MS

Mr. Mritunjay Singh (61)

Executive Director

123.60 M INR
MS

Mrs. Madhurima Singh (59)

Executive Director · since 2021

110.90 M INR
SS

Mr. Srinivas Singh

Executive Director · since 2022

106.10 M INR
SS

Mr. Sarvesh Singh (43)

Executive Director · since 2019

48.70 M INR
NA

Mr. Narendra Aneja (73)

Independent Director

3.84 M INR

Frequently asked questions about Alkem Laboratories

The business model of Alkem Laboratories Ltd revolves around the manufacturing and marketing of pharmaceutical products. As a leading Indian pharmaceutical company, Alkem Laboratories focuses on developing, producing, and distributing a wide range of generic and branded drugs across various therapeutic segments. With a strong emphasis on research and development, Alkem Laboratories aims to consistently bring innovative and affordable healthcare solutions to patients globally. By adhering to stringent quality standards and regulatory requirements, the company strives to maintain its reputation for delivering safe, effective, and high-quality medications. Alkem Laboratories Ltd is committed to improving healthcare accessibility and contributing to a healthier society.

Alkem Laboratories Ltd is primarily active in the pharmaceutical industry.

The main competitors of Alkem Laboratories Ltd in the market are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Torrent Pharmaceuticals Ltd.

Alkem Laboratories Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1973, Alkem has consistently shown remarkable growth and has become one of India's leading pharmaceutical enterprises. The company is primarily engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical products for both domestic and international markets. Alkem Laboratories Ltd. has earned a stellar reputation for its high-quality products, state-of-the-art manufacturing facilities, and extensive research and development capabilities. With a strong focus on innovation and compliance with global quality standards, Alkem Laboratories Ltd. continues to make a significant impact in the healthcare industry, contributing to the overall wellness and patient care.

Alkem Laboratories Ltd has achieved several significant milestones throughout its journey. The company expanded its operations globally by establishing subsidiaries and offices in multiple countries. It received various certifications and accreditations, including the US FDA approvals for several of its manufacturing facilities. Alkem Laboratories Ltd has consistently focused on research and development, leading to the successful launch of innovative and affordable pharmaceutical products. Additionally, the company has fostered strong partnerships with renowned global pharmaceutical companies, enabling it to expand its product portfolio. Alkem Laboratories Ltd continues to demonstrate its commitment to excellence and is regarded as a leading player in the pharmaceutical industry.

Alkem Laboratories Ltd is primarily present in multiple countries and regions worldwide. Some of the key areas where Alkem operates include India, the United States, Europe, Latin America, and various Asian and African countries. With a strong global presence, Alkem Laboratories has established a robust network and continually expands its reach to cater to diverse markets.

Alkem Laboratories Ltd represents values of integrity, quality, and innovation. The company prioritizes ethical business practices and strives for excellence in product manufacturing and distribution. Alkem Laboratories believes in delivering high-quality healthcare solutions to improve patients' lives. The company's corporate philosophy revolves around continuously investing in research and development, fostering a culture of learning and growth, and maintaining strong relationships with healthcare professionals and stakeholders. By upholding these values, Alkem Laboratories positions itself as a trusted and reliable pharmaceutical company in the market.

Analysts currently set an average price target of 5,966.79 INR for the Alkem Laboratories stock (median: 6,007.80 INR), implying +6.6 % versus the latest price. The consensus is based on 27 analyst ratings.

Alkem Laboratories Analyst Price Targets 2026

27 analysts currently rate the Alkem Laboratories stock: 15 recommend buying, 9 holding and 3 selling. For 2026, analysts expect Alkem Laboratories to generate revenue of 146.21 B INR and earnings per share of 210.42 INR.

Alkem Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Alkem Laboratories share trades at 50.83 EUR (5,598.50 INR).

Alkem Laboratories Ltd is a leading pharmaceutical company based in India and operates globally. The company is involved in various divisions, including generics, branded generics, OTC products, APIs, and biosimilars. The generics division of Alkem Laboratories Ltd is one of the largest in India, covering a wide range of therapeutic areas. The company also produces a variety of branded generics under the name "Alkem's Brand," including dermatology, gastroenterology, cardiology, neurology, and gynecology products. Alkem Laboratories Ltd also offers a range of OTC products, including antacids, pain relievers, cough and cold products, vitamins, and minerals. They have a strong presence in this market segment and their products are available in India and other countries. Additionally, the company is involved in API production, which serve as key intermediates for drug manufacturing. They have a wide range of APIs used in various therapeutic areas. Alkem Laboratories Ltd is also involved in the development of biosimilars, with a strong pipeline in various stages of development, covering areas such as oncology, autoimmune diseases, and diabetes. The company has a strong presence in India and operates globally, with a focus on providing high-quality and affordable medicines that meet customer needs. They invest in research and development to continually develop new products and have a strong distribution infrastructure to quickly bring products to market and strengthen their presence. Overall, Alkem Laboratories Ltd aims to offer a wide range of products and divisions to meet market demand, with a strong team and modern infrastructure positioning them to expand their market presence in India and globally. The business model of Alkem Laboratories Ltd is focused on providing high-quality and affordable medicines that meet customer needs.

The expected revenue of Alkem Laboratories is 146.21 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alkem Laboratories is 25.16 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alkem Laboratories is currently 26.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alkem Laboratories stock.

The price-to-sales ratio (P/S) of Alkem Laboratories is currently 4.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alkem Laboratories stock.

The Eulerpool Quality Score for Alkem Laboratories is 7/10.

The ISIN of Alkem Laboratories is INE540L01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Alkem Laboratories is ALKEM.NS. The ticker symbol is used to trade Alkem Laboratories shares on the stock exchange.

Over the past 12 months, Alkem Laboratories paid a dividend of 45.00 INR . This corresponds to a dividend yield of about 0.80 %. For the coming 12 months, Alkem Laboratories is expected to pay a dividend of 61.20 INR.

The current dividend yield of Alkem Laboratories is 0.80 %.

Alkem Laboratories pays a dividend, distributed in the months of , , , .

Alkem Laboratories paid dividends every year for the past 10 years.

For the upcoming 12 months, dividends amounting to 61.20 INR are expected. This corresponds to a dividend yield of 1.09 %.

Alkem Laboratories is assigned to the 'Health' sector.

To receive the latest dividend of Alkem Laboratories from amounting to 43 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Alkem Laboratories distributed 45 INR as dividends.

The dividends of Alkem Laboratories are distributed in INR.

All fundamentals and in-depth analysis of Alkem Laboratories

Our stock analysis for Alkem Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alkem Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Alkem Laboratories Stock
Alkem Laboratories Revenue→
Alkem Laboratories Stock
Alkem Laboratories Net Income→
Alkem Laboratories Stock
Alkem Laboratories P/E→
Alkem Laboratories Stock
Alkem Laboratories P/S→
Alkem Laboratories Stock
Alkem Laboratories EBIT→
Alkem Laboratories Stock
Alkem Laboratories Dividend→
Alkem Laboratories Stock
Alkem Laboratories Directors Dealings→
Alkem Laboratories Stock
Alkem Laboratories Stocks→
Alkem Laboratories Stock
Alkem Laboratories Market capitalization→
Alkem Laboratories Stock
Alkem Laboratories Debt→
Alkem Laboratories Stock
Alkem Laboratories Liabilities→
Alkem Laboratories Stock
Alkem Laboratories Equity→
Alkem Laboratories Stock
Alkem Laboratories AAQS→
Alkem Laboratories Stock
Alkem Laboratories Employees→
Alkem Laboratories Stock
Alkem Laboratories ROE→
Alkem Laboratories Stock
Alkem Laboratories ROA→
Alkem Laboratories Stock
Alkem Laboratories ROCE→
Alkem Laboratories Stock
Alkem Laboratories News→
Alkem Laboratories Stock
Alkem Laboratories Analyst Price Targets→

Health Stocks

Alkermes PlcALK-Abello A/SAllarity TherapeuticsAlivus Life SciencesAllergy TherapeuticsAligos TherapeuticsAllgens Medical Technology CoAligned GeneticsAllianca Saude e ParticipacoesAlign TechnologyAlliance Healthcare GroupAlgorae PharmaceuticalsAll Stocks A–Z →